A carregar...
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation
Eculizumab inhibits the terminal, lytic pathway of complement by blocking the activation of the complement protein C5 and shows remarkable clinical benefits in certain complement-mediated diseases. However, several reports suggest that activation of C5 is not always completely suppressed in patients...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5324716/ https://ncbi.nlm.nih.gov/pubmed/28028023 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-08-732800 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|